Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1745, Issue 3, 2005, Pages 318-329

  Natoni, Federica ^a   Diolordi, Laura ^a   Santoni, Claudio ^a   Gilardini Montani, Maria Saveria ^a  

^a UNIVERSITY OF TUSCIA   (Italy)

Author keywords

Apoptosis; Bcl 2 family; Fas; FLIP; Pancreatic cancer; Sodium butyrate

Indexed keywords

BUTYRIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; FAS ANTIBODY; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE; PROTEIN BCL 2; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY;

APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; BUTYRATES; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; DNA PRIMERS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIAL MEMBRANES; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRAZOLIUM SALTS; THIAZOLES;

EID: 24944504460     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2005.07.003     Document Type: Article

References (43)

1. R.T. Greenlee, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics 2000 CA Cancer J. Clin. 50 2000 7 33
2. R.A. Wolff, P. Chiao, R. Lenzi, P.W. Pisters, J.E. Lee, N.A. Janjan, C.H. Crane, D.B. Evans, and J.L. Abbruzzese Current approaches and future strategies for pancreatic carcinoma Invest. New Drugs 18 1 2000 43 56
3. M. Buchler, H. Friess, K.H. Schultheiss, C. Gebhardt, R. Kubel, K.H. Muhrer, M. Winkelmann, T. Wagener, R. Klapdor, and M. Kaul A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer Cancer 68 1991 1507 1512
4. W. Scheithauer, G. Kornek, K. Haider, and D. Depisch Unresponsiveness of pancreatic adenocarcinoma to antiestrogen therapy Eur. J. Cancer 26 7 1990 851 852
5. D.E. Fisher Apoptosis in cancer therapy: crossing the threshold Cell 78 1994 539 542
6. C.B. Thompson Apoptosis in the pathogenesis and the treatment of disease Science 267 1995 1456 1462
7. S. Nagata Apoptosis by death factor Cell 88 1997 355 365
8. S. Yonehara, A. Ishii, and M. Yonehara A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor factor J. Exp. Med. 169 5 1989 1747 1756
9. J.P. Medema, C. Scaffidi, F.C. Kischkel, A. Shevchenko, M. Mann, P.H. Krammer, and M.E. Peter FLICE is activated by association with the CD95 death-inducing signaling complex (DISC) EMBO J. 16 10 1997 279 280
10. J.M. Adams, and S. Cory The Bcl-2 protein family: arbiters of cell survival Science 281 1998 1322 1326
11. J.H. Cummings Short chain fatty acids in the human colon Gut 22 1981 763 779
12. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 15 2000 1210 1216
13. E.P. Candido, R. Reeves, and J.R. Davie Sodium butyrate inhibits histone deacetylation in cultured cells Cell 14 1978 105 113
14. M. Grunstein Histone acetylation and chromatin structure and transcription Nature 389 1997 349 352
15. S.Y. Archer, S. Meng, A. Shei, and R.A. Hodin P21 is required for butyrate-mediated growth inhibition of human colon cancer cells Proc. Natl. Acad. Sci. 95 1998 6791 6796
16. M.C. Madigan, G. Chaudhri, P.L. Penfold, and R.M. Conway Sodium butyrate modulates p53 and Bcl-2 expression in human retinoblastoma cell lines Oncol. Res. 11 7 1999 331 337
17. X. Li, M. Marani, R. Mannucci, B. Kinsey, F. Andriani, I. Nicoletti, L. Denner, and M. Marcelli Overexpression of BCL-X (L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells Cancer Res. 61 4 2001 1699 1706
18. L.C. Tsai, M.W. Hung, G.G. Chang, and T.C. Chang Apoptosis induced by the sodium butyrate in human gastric cancer TMK-1 cells Anticancer Res. 20 2000 2441 2448
19. D.A. Litvak, K.O. Hwang, B.M. Evers, and C.M. Townsend Induction of apoptosis in human gastric cancer by sodium butyrate Anticancer Res. 20 2000 779 784
20. I. Hara, H. Miyake, S. Hara, S. Arakawa, and S. Kamidono Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity Int. J. Oncol. 17 6 2000 1213 1218
21. C. Giardina, H. Boulares, and M.S. Inan NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species Biochim. Biophys. Acta 1448 3 1999 425 438
22. A. Hernandez, R. Thomas, F. Smith, J. Sandberg, S. Kim, D.H. Chung, and B.M. Evers Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis Surgery 130 2 2001 265 272
23. P. Chomczynski, and N. Sacchi Single-step method of mRNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal. Biochem. 162 1987 156 159
24. S.A. Adam, R.S. Marr, and L. Gerace Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors J. Cell Biol. 111 1990 807 811
25. P.A. Marks, R.A. Rifkind, V.M. Richon, and R. Breslow Inhibitors of histone deacetylase are potentially effective anticancer agents Clin. Cancer Res. 7 2001 759 760
26. J. Kruh Effects of sodium butyrate, a new pharmacological agent on cells in culture Mol. Cell Biochem. 42 1982 65 82
27. E.J. Bloom, B. Siddiqui, J.W. Hicks, and Y.S. Kim Effect of sodium butyrate, a differentiating agent, on cell surface glycoconjugates of a human pancreatic cell line Pancreas 4 1 1989 59 64
28. T.D. Mullins, H.F. Kern, and R.S. Metzgar Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines Pancreas 6 5 1991 578 587
29. T. Gaschott, C.-U. Maaben, and J. Stein Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells Anticancer Res. 21 2001 2815 2820
30. J.D. Evans, P.A. Cornford, A. Dodson, W. Greenhalf, C.S. Foster, and J.P. Neoptolemos Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas Pancreatology 1 2001 254 262
31. D. Campani, I. Esposito, U. Boggi, D. Cecchetti, M. Menicagli, F. De Negri, L. Colizzi, M. Del Chiaro, F. Mosca, G. Fornaciari, and G. Bevilacqua Bcl-2 expression in pancreas development and pancreatic cancer progression J. Pathol. 194 2001 444 450
32. Y. Miyamoto, R. Hosotani, M. Wada, J.U. Lee, T. Koshiba, K. Fujimoto, S. Tsuji, S. Nakajima, R. Doi, M. Kato, Y. Shimada, and M. Imamura Immunohistochemical analysis of Bcl-2, Bax, Bcl-X and Mcl-1 expression in pancreatic cancers Oncology 56 1999 73 82
33. H. Friess, Z. Lu, A. Andren-Sandberg, P. Berberat, A. Zimmermann, G. Adler, R. Schmid, and M.W. Buchler Moderate activation of the apoptosis inhibitor Bcl-XL worsen the prognosis in pancreatic cancer Ann. Surg. 228 1998 780 787
34. Z.-W. Xu, H. Friess, M. Solioz, S. Aebi, M. Korc, J. Kleef, and M.W. Buchler Bcl-xL antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine Int. J. Cancer 94 2001 268 274
35. S. Westphal, and H. Kalthoff Apoptosis: targets in pancreatic cancer Mol. Cancer 2 2003 6 20
36. P.S. Moore, S. Barbi, M. Donadelli, C. Costanzo, C. Bassi, M. Palmieri, and A. Scarpa Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells Biochim. Biophys. Acta 1693 2004 167 176
37. J.A. McBain, A. Eastman, D.L. Simmons, G.R. Pettit, and G.C. Mueller Phorbol ester augments butyrate-induced apoptosis of colon cancer cells Int. J. Cancer 67 5 1996 715 723
38. H. Ungefroren, M. Voss, M. Jansen, C. Roeder, D. Henne-Bruns, B. Kremer, and H. Kalthoff Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis Cancer Res. 58 1998 1741 1749
39. W. von Bernstorff, R.A. Spanjaard, A.K. Chan, D.C. Lockhart, N. Sadanaga, I. Wood, M. Peiper, P.S. Goedegebuure, and T.J. Eberlein Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand Surgery 125 1 1999 73 84
40. B. Bonnotte, N. Favre, S. Reveneau, O. Micheau, N. Droin, C. Garrido, A. Fontana, B. Chauffert, E. Solary, and F. Martin Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate Cell Death Differ. 5 6 1998 480 487
41. D. Bernhard, S. Skvortsov, I. Tinhofer, H. Hubl, R. Greil, A. Csordas, and R. Kofler Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts Cell Death Differ. 8 10 2001 1014 1021
42. H. Luhrs, T. Kudlich, M. Neumann, J. Schauber, R. Melcher, A. Gostner, W. Scheppach, and T.P. Menzel Butyrate-enhanced TNFalpha-induced apoptosis is associated with inhibition of NF-kappaB Anticancer Res. 22 3 2002 1561 1568
43. W. Wang, J.L. Abbruzzese, D.B. Evans, L. Larry, K.R. Cleary, and P.J. Chiao The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin. Cancer Res. 5 1 1999 119 127